Colorectal adenocarcinoma – Diagnostics – Overview of Information and Clinical Research

Colorectal adenocarcinoma is the most common type of cancer affecting the colon and rectum, often beginning as small growths called polyps that can develop into cancer over many years. Understanding how this disease is detected and diagnosed is crucial for effective treatment and improved outcomes.

Introduction: Who Should Seek Diagnostic Testing

Colorectal cancer does not always announce itself with clear symptoms, especially in its early stages. This makes knowing when to seek diagnostic testing particularly important. People who are 45 years old or older should talk to their doctor about screening, even if they feel perfectly healthy^[6]. This age recommendation reflects recent changes, as medical experts have noticed an increase in colorectal cancer cases among younger adults over the past 15 years^[4].

You should seek medical attention if you notice certain warning signs that persist. These include blood appearing on or in your stool, which might look dark, bright red, or cause your poop to appear black and tarry^[4]. Persistent changes in how you use the bathroom—such as ongoing constipation, diarrhea, or feeling like you still need to go after you’ve already been—warrant a conversation with a healthcare provider^[4]. Other concerning symptoms include unexplained belly pain that doesn’t go away or hurts significantly, a bloated stomach lasting more than a week, unexplained weight loss, and persistent tiredness or weakness^[1]^[4].

It’s essential to understand that having symptoms doesn’t necessarily mean you have cancer. Many of these signs can result from less serious conditions like hemorrhoids, infections, or irritable bowel syndrome^[7]. However, it’s always better to check with a healthcare provider when you notice unusual or persistent changes in your body.

Certain individuals face higher risk and may need earlier or more frequent screening. If you have a first-degree relative—a parent, sibling, or child—with a history of colon or rectal cancer, your risk increases^[8]. People with a personal history of colon, rectal, or ovarian cancer, or those who have had high-risk adenomas (polyps that are 1 centimeter or larger, or have abnormal-looking cells), should discuss appropriate screening schedules with their doctors^[8]. Additionally, if you have chronic ulcerative colitis or Crohn disease for 8 years or more, or if you have inherited gene changes that increase risk for familial adenomatous polyposis or Lynch syndrome, you may need specialized screening approaches^[8].

⚠️ Important

Many people with colorectal cancer have no symptoms in the early stages, when the disease is most treatable. This is why regular screening is so important, even when you feel completely well. Screening can detect precancerous polyps before they turn into cancer, potentially preventing the disease altogether^[6].

Classic Diagnostic Methods

When symptoms appear or screening tests suggest possible colorectal cancer, doctors use several established methods to confirm a diagnosis and understand the extent of the disease. These diagnostic tools help distinguish colorectal adenocarcinoma from other conditions and provide crucial information for planning treatment.

Blood Tests

Blood tests serve multiple purposes in the diagnostic process, though they cannot directly diagnose colon cancer on their own. Doctors look for certain signs related to liver and kidney function, blood count, and other factors that might suggest the possibility of colon cancer^[1]. A blood test might reveal a low level of red blood cells, which could indicate that a colon cancer is causing bleeding^[1].

Some colorectal cancers produce a protein called carcinoembryonic antigen, or CEA. Blood tests can track the level of CEA over time, helping doctors understand whether cancer is responding to treatment or if it has returned after treatment ends^[10]. However, CEA is primarily useful for monitoring rather than initial diagnosis.

Colonoscopy

Colonoscopy is one of the most important diagnostic tools for colorectal cancer. During this procedure, a doctor inserts a long, thin, flexible tube with a camera attached—called a colonoscope—into the rectum to examine the entire colon^[1]. The camera sends images to a monitor, allowing the doctor to look for polyps or other unusual areas throughout the colon.

What makes colonoscopy particularly valuable is that doctors can do more than just look. They can pass surgical tools through the tube to remove tissue samples for testing or to remove polyps entirely during the same procedure^[10]. This dual capability—both examining and treating—makes colonoscopy a cornerstone of colorectal cancer diagnosis.

The procedure requires preparation beforehand, typically involving dietary changes and bowel cleansing to ensure the doctor can see the colon lining clearly. While the preparation can be uncomfortable, the examination itself is usually performed under sedation to minimize discomfort.

Biopsy

A biopsy involves removing a small piece of tissue from the colon or rectum for laboratory testing^[1]. This tissue sample is often collected during a colonoscopy when the doctor sees suspicious areas. In some cases, surgery may be needed to obtain the tissue sample.

In the laboratory, specialists examine the cells under a microscope to determine whether they are cancerous. They also conduct tests to show how quickly the cells are growing and other characteristics of the cancer cells^[10]. Your healthcare team uses these results to understand your prognosis and create an appropriate treatment plan. The biopsy provides definitive confirmation of whether cancer is present and what type it is.

Imaging Tests

Various imaging tests take detailed pictures of your colorectal area and other parts of your body to look for polyps, tumors, or signs that cancer has spread. These tests use different technologies to create images that help doctors see inside your body without surgery.

X-rays use radiation to create pictures of the inside of your body. The x-ray beam is absorbed differently by various body structures, creating distinct images^[1].

Ultrasound creates real-time pictures of the inside of the body using sound waves rather than radiation^[1]. This technology is safe and painless, using a device placed on the skin or inserted into the rectum to generate images.

MRI scans (magnetic resonance imaging) use magnets, radio waves, and a computer to create detailed images of your body’s soft tissues^[1]. Unlike x-rays or CT scans, MRI doesn’t use radiation, making it particularly useful for certain situations.

PET/CT scans combine two imaging techniques. A PET scan uses a small amount of radioactive material to show how tissues and organs are functioning, while the CT scan provides detailed anatomical images^[1]. Together, they help doctors see both the structure and function of tissues, which is valuable for detecting cancer spread.

After colorectal cancer has been diagnosed, imaging tests help determine if cancer cells have spread within the colon or to other parts of the body^[8]. This information is crucial for determining the stage of cancer and planning appropriate treatment.

Additional Procedures

Sigmoidoscopy is similar to colonoscopy but examines only the lower part of the colon (the sigmoid colon) and rectum. This procedure uses a shorter, flexible tube with a camera and may be appropriate in certain situations, though it doesn’t examine the entire colon like a full colonoscopy does.

Proctoscopy specifically examines the rectum and may be recommended every 3-6 months for the first two years for patients with rectal cancer who had certain types of surgery^[21].

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments for colorectal cancer, and specific diagnostic tests serve as standard criteria for determining whether patients can enroll in these studies. Understanding these qualification requirements helps patients and doctors identify appropriate trial opportunities.

Many clinical trials require confirmation of the cancer diagnosis through biopsy, where laboratory specialists examine tissue samples to verify the presence of adenocarcinoma cells. The biopsy results must show specific characteristics of the cancer cells, including how they appear under the microscope and how quickly they’re growing^[10].

The stage of cancer—determined through imaging tests and physical examinations—often determines trial eligibility. Trials may specifically seek patients with early-stage cancer, advanced cancer, or cancer that has spread to other organs. Doctors use colonoscopy findings, CT scans, MRI scans, and PET scans to accurately stage the disease before considering trial enrollment.

Blood tests play an important role in trial qualification by providing information about overall health and organ function. Trials typically require blood tests showing that the kidneys and liver are working adequately^[1]. Some trials may measure CEA levels to establish a baseline for monitoring treatment effectiveness.

Certain clinical trials focus on specific molecular characteristics of tumors. For these studies, additional specialized testing of biopsy samples may be required. Some trials target cancers with high microsatellite instability (MSI-H) or DNA mismatch repair deficiency (dMMR)—specific genetic characteristics that affect how cells repair DNA damage. Laboratory tests on tumor tissue can identify these features, determining whether a patient qualifies for trials testing immunotherapy approaches that work particularly well for these cancer types.

Imaging tests must often show measurable disease that can be tracked over time. This allows researchers to determine whether the treatment being studied is working. CT scans or MRI scans taken before starting a clinical trial provide baseline measurements that doctors compare with scans taken during and after treatment.

Some trials require proof that cancer has not spread to certain areas, particularly the brain. This might involve MRI scans of the brain to ensure patients meet the trial’s inclusion criteria. Other trials specifically seek patients whose cancer has spread, requiring imaging evidence of metastatic disease—cancer that has traveled from the original site to distant organs.

⚠️ Important

Clinical trials have specific eligibility criteria designed to test treatments in particular patient populations. Just because you don’t qualify for one trial doesn’t mean you won’t qualify for others. Work with your healthcare team to identify trials that match your specific situation, and remember that standard treatments remain available regardless of trial participation.

Performance status assessments—measurements of how well you can perform daily activities—also factor into trial eligibility. While not a traditional diagnostic test, doctors evaluate your ability to care for yourself and engage in normal activities. This assessment helps ensure that patients enrolled in trials can safely tolerate the experimental treatments being studied.

Previous treatment history matters for many trials. Some studies specifically seek patients who haven’t yet received treatment, while others look for patients whose cancer didn’t respond to standard therapies. Your medical records documenting prior diagnostic procedures, treatments received, and how your cancer responded provide essential information for trial qualification.

Prognosis and Survival Rate

Prognosis

The outlook for patients with colorectal adenocarcinoma varies significantly depending on several important factors. The stage at which cancer is diagnosed plays the most crucial role in determining prognosis. Early-stage cancers that haven’t spread beyond the colon or rectum have much better outcomes than advanced-stage cancers that have traveled to other parts of the body^[9].

When colorectal cancer is found early through screening, before symptoms develop, the prognosis is generally favorable. Only about 40% of colorectal cancers are currently diagnosed at an early stage, largely because screening tests remain underused^[5]. This highlights the critical importance of regular screening, as early detection dramatically improves the chances of successful treatment and long-term survival.

Several factors beyond stage affect how the disease progresses. The specific characteristics of cancer cells—including how quickly they’re growing and their molecular features—influence treatment response and outcomes^[10]. Overall health status matters significantly; patients in better physical condition generally tolerate treatments better and experience improved outcomes. Age also plays a role, though colorectal cancer can affect people at any age, with most cases occurring in people over 50^[3].

Timely diagnosis and appropriate treatment are essential for improving survival rates and quality of life^[9]. Regular follow-up care after treatment helps detect any recurrence early, when it’s most treatable. Thanks to advances in screening tests, early detection, and new types of treatment, fewer people are dying from colon cancer than in previous decades^[4].

Survival Rate

Survival rates for colorectal cancer demonstrate the profound impact of early detection. When colorectal cancer is diagnosed at an early stage—before it has spread beyond the colon or rectum—the survival rate is highly favorable at 90%^[5]. This means that nine out of ten people diagnosed with early-stage colorectal cancer survive their disease.

The prognosis becomes less favorable as cancer advances to later stages. Advanced-stage cancers, where the disease has spread to distant organs, have lower survival rates than early-stage disease^[9]. This stark difference in outcomes based on stage emphasizes why early detection through regular screening is so critical—it literally saves lives by catching cancer when it’s most treatable.

Colorectal cancer is the second leading cause of cancer-related deaths worldwide. In 2020, more than 930,000 deaths due to colorectal cancer were estimated to have occurred globally^[9]. However, there is encouraging news: incidence rates of colorectal cancer have been decreasing in high-income countries, largely as a result of effective screening programs^[9]. This demonstrates that when people have access to screening and use it, deaths from colorectal cancer can be prevented.

It takes approximately 10 to 15 years for a colon polyp to develop into cancer, and early screening can prevent this transformation entirely^[1]. This long timeline provides a significant window of opportunity for detection and prevention, making colorectal cancer one of the most preventable types of cancer when appropriate screening measures are followed.